Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 7/20 | 0.44 |
| ▸ | CTSA | P10619 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.36 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | COASY | Q13057 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | PTGFR | P43088 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30645020 | 0.90 | CTSA (0.39) | SOS1CTSACOASYPDE2APTGFR | |
| SCHEMBL20743169 | 0.90 | CTSA (0.39) | SOS1CTSACOASYPDE2APTGFR | |
| SCHEMBL20762257 | 0.89 | CTSA (0.39) | SOS1CTSAHDAC1HDAC6HDAC5 | |
| SCHEMBL20743101 | 0.88 | SOS1 (0.46) | SOS1CTSAHDAC1HDAC6HDAC5 | |
| SCHEMBL30645115 | 0.88 | SOS1 (0.46) | SOS1CTSAHDAC1HDAC6HDAC5 | |
| SCHEMBL19283565 | 0.88 | GRIN1 (0.40) | SOS1CTSAGRIN1GRIN2BPTGFR | |
| SCHEMBL20744168 | 0.85 | SOS1 (0.43) | SOS1CTSACOASY | |
| SCHEMBL30645108 | 0.85 | SOS1 (0.43) | SOS1CTSACOASY | |
| SCHEMBL20743019 | 0.84 | SOS1 (0.45) | SOS1CTSAHDAC1HDAC6HDAC5 | |
| SCHEMBL20743145 | 0.83 | SOS1 (0.41) | SOS1CTSAHDAC1HDAC6HDAC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111344281-B | Potassium channel inhibitors substituted benzimidazoles | 阿塞西翁制药公司 | 2023-11-14 | — | — | CN | claimed |
| US-20200216398-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2020-07-09 | — | — | US | claimed |
| CN-111344281-A | Potassium channel inhibitors of substituted benzimidazoles | 阿塞西翁制药公司 | 2020-06-26 | — | — | CN | claimed |
| EP-3668841-A1 | SUBSTITUTED BENZIMIDAZOLES AS POTASSIUM CHANNEL INHIBITORS | Acesion Pharma ApS (DK) | 2020-06-24 | — | — | EP | claimed |
| WO-2019034603-A1 | SUBSTITUTED BENZIMIDAZOLES AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2019-02-21 | — | — | WO | claimed |
| CN-111344281-B | Potassium channel inhibitors substituted benzimidazoles | 阿塞西翁制药公司 | 2023-11-14 | — | — | CN | disclosed |
| US-20200216398-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2020-07-09 | — | — | US | disclosed |
| US-20200216398-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2020-07-09 | — | — | US | disclosed |
| CN-111344281-A | Potassium channel inhibitors of substituted benzimidazoles | 阿塞西翁制药公司 | 2020-06-26 | — | — | CN | disclosed |
| EP-3668841-A1 | SUBSTITUTED BENZIMIDAZOLES AS POTASSIUM CHANNEL INHIBITORS | Acesion Pharma ApS (DK) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019034603-A1 | SUBSTITUTED BENZIMIDAZOLES AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216398-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | KCNN1, KCNN2, KCNJ2 | SOS1 3161/4885CTSA 2301/4885HDAC1 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.